Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 25 Publications

11 Customer Reviews

  • FACS profiles for cell cycle synchronization of HCT116 cells pulsed with EdU. Asynchronous (AS) HCT116 cells were treated with CDK4/6i (Palbociclib, 2 μM) for 20 hours to arrest in G0/G1 (middle panel), followed by a wash in fresh media for 8 hours to release into S phase (right panel).

    Cell, 2018, 174(5):1127-1142. Palbociclib (PD-0332991) HCl purchased from Selleck.

    SK-HEP-1 cells were plated in the presence or absence of the CDK inhibitor (Roscovitine 10 mM; Palbociclib 500 nM). 18 hours after plating, cells were rinsed once with serum-free medium and incubated with delipidated medium containing the CDK inhibitor for 6 hours.

    Cell, 2018, doi:10.1016/j.cell.2018.11.011. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 NX\BeXJYU2mwYYPlJGF{e2G7 NVXIZXc1OjRiaB?= NH\ZOHhKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= NX7IS|lrOjR4NEGxNFM>
COLO205 MofkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWi3NkBp MoS1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjB|NjFOwG0> MWGyOFY1OTFyMx?=
U937 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln2O|IhcA>? MlXWRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6lb4Lwc5JifGmxbjDv[kBcO0ifdHj5cYllcW6nIHnueI8hTE6DIIfpeIghUUN3MDDv[kAxNjF2IN88US=> M1rxVVI1PjRzMUCz
MOLM13 NEe3NoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXOZ|cyPzJiaB?= NWPyN3J5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNU2xOOTNiY3XscJMhcGG{Yn;ybY5oKE[OVEOgTXRFKG23dHHueEBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? MnrnNlQ3PDFzMEO=
MOLM13 Ml\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjMW5FRPzJiaB?= MlHCRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDzc5Ji\mWwaXKtdoV{cXO2YX70JIh2dWGwIF3PUG0yOyClZXzsd{Bie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMEm2JO69VQ>? MXGyOFY1OTFyMx?=
MDA-MB-435 NY\IWZNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;4NlQhcA>? NFzGeoFKSzVyPUCuNVYh|ryP NX;JcYFROTV6MEG4N|E>
K562 MojIR5l1d3SxeHnjJGF{e2G7 MX[5OkBp MVHEUXNQ Mnm5TWM2OD1{IN88US=> NHHzcGQzPDRzN{W2Oi=>
DU145 NWrHeHltS3m2b4TvfIlkKEG|c3H5 NFixNXo6PiCq NWXueHBCTE2VTx?= M2fLVmlEPTB;Nz61JO69VQ>? M2fnb|I1PDF5NU[2
MDA-MB-231 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XsbFEh|ryP MUKyOEBp M3XWdWROW09? NXTobVJCS2WubDDjfYNt\SCjcoLld5Qh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdzIIDoZZNm NIe1TGgzPDRzN{W2Oi=>
MCF7 NUH6UI9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqz[VI1OSEQvF2= NF\mblAzPCCq MXzEUXNQ MnzCR4VtdCCleXPs[UBienKnc4SgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIHH0JGcyKHCqYYPl M{TzXFI1PDF5NU[2
MCF7 Mn;OT4lv[XOnIFHzd4F6 MWi1JO69VQ>? MWKyOEBp MoriSG1UVw>? M4XUSmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= NFv2ZXYzPDRzN{W2Oi=>
MDA-MB-231 M{jYVGtqdmG|ZTDBd5NigQ>? NWPYVnptPSEQvF2= NIrYXmszPCCq MXrEUXNQ M4nKbWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= NInCW4gzPDRzN{W2Oi=>
MDA-MB-231 MWXGeY5kfGmxbjDBd5NigQ>? M2nFWFEuOTBizszN M4W0U|I1KGh? M4LDXmROW09? M174coRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= NYLxdIZHOjR2MUe1OlY>
MCF7 M1r5cmZ2dmO2aX;uJGF{e2G7 NXLseohtOS1zMDFOwG0> MYqyOEBp M3LoSmROW09? MYXkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? MonZNlQ1OTd3Nk[=
MDA-MB-231 MmnDSpVv[3Srb36gRZN{[Xl? NWH2cmNsOC53LUGg{txO NUexdFNxPDhiaB?= NHPqe5BFVVOR NYDaWFRScGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? NX34dm5VOjR2MUe1OlY>
MCF7 MkjvSpVv[3Srb36gRZN{[Xl? MUKwMlUuOSEQvF2= NV;xVHRKPDhiaB?= NWH3PZNjTE2VTx?= M4fvVIhieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm M4DMPVI1PDF5NU[2
697 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTRTWM2OD1zNEiuN|ghdk1? M{\NO3NCVkeHUh?=
P12-ICHIKAWA NXz2Oow2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTl4LkC0JI5O M{HjZnNCVkeHUh?=
NB69 M2nQUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLOOY1KSzVyPUG2NU45KG6P MmrrV2FPT0WU
EoL-1 NXjhN5Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnlW3RKSzVyPUG4O{4zPiCwTR?= NWmxWIU5W0GQR1XS
BHT-101 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfNTWM2OD1zOUiuNlUhdk1? M{DNTHNCVkeHUh?=
SK-NEP-1 NVLYU3ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmm1TWM2OD1{MkCuNFIhdk1? M3Lx[3NCVkeHUh?=
MHH-NB-11 NEnq[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjY[m9OUUN3ME2yNlAvOTlibl2= MVfTRW5ITVJ?
AsPC-1 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4njemlEPTB;MkWyMlU{KG6P NXL1PYxZW0GQR1XS
ES1 M1fsd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7VXHpFUUN3ME2yOVYvOjVibl2= MYLTRW5ITVJ?
LAMA-84 M4DNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjxcVBKSzVyPUK1PE4yQSCwTR?= MorQV2FPT0WU
MOLT-16 M4HLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3ZeoY4UUN3ME2yOVgvPDlibl2= Mo\EV2FPT0WU
ES7 M2q1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEL3RZhKSzVyPUK3N{4xQSCwTR?= MoD3V2FPT0WU
KY821 NX\xWY5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHaTWM2OD1|MUSuNUBvVQ>? M3zSSnNCVkeHUh?=
RT-112 NE\HOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfZSVRVUUN3ME2zNlEvODVibl2= NYC0OoV{W0GQR1XS
HL-60 NF7YZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTN2MD62OkBvVQ>? NIXI[nhUSU6JRWK=
MOLT-4 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmCzTWM2OD1|NEWuNVMhdk1? NYO0VoRHW0GQR1XS
KARPAS-45 Mkj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoC0TWM2OD1|N{[uNVYhdk1? NH7u[IlUSU6JRWK=
SK-N-AS M1fKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXKTWM2OD1|OEeuPFMhdk1? NVTDcFd[W0GQR1XS
CTB-1 NFqxbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3n6T2lEPTB;NEC1MlAzKG6P M{H0[XNCVkeHUh?=
NKM-1 NHTFdIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvjTWM2OD12MUGuPFkhdk1? Mnq4V2FPT0WU
HTC-C3 M1TuNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfVZ3ZKSzVyPUSzNk46PSCwTR?= NHnqT3ZUSU6JRWK=
BE-13 NF21[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13WSGlEPTB;NES0MlI4KG6P MWDTRW5ITVJ?
KOSC-2 MnLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3qfGpvUUN3ME20OlYvQSCwTR?= NHXQbFBUSU6JRWK=
NB14 NV32THMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGryVnFKSzVyPUS4N{42QCCwTR?= MkTnV2FPT0WU
CAL-27 NVvweHZjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXpc|RKSzVyPUS5OE42QSCwTR?= M2rrV3NCVkeHUh?=
H9 M3nEUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml73TWM2OD12OUWuOFMhdk1? M1fvTnNCVkeHUh?=
RS4-11 NWXmPYI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPmbplKSzVyPUWwOE44OyCwTR?= MVHTRW5ITVJ?
PA-1 M2HSZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:0cmRKSzVyPUWwPU45PiCwTR?= NXLGOlBzW0GQR1XS
MV-4-11 M{jCOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTVzMz64OUBvVQ>? M4nUZ3NCVkeHUh?=
OS-RC-2 NH[3e29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILVVlVKSzVyPUWyNU43OiCwTR?= NULDWG9OW0GQR1XS
RPMI-8226 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTV{Nj64OkBvVQ>? NGHzPW5USU6JRWK=
HGC-27 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LEfmlEPTB;NU[0Mlk6KG6P NHjadm5USU6JRWK=
CHP-212 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTV7Mz61PUBvVQ>? M3K5UnNCVkeHUh?=
NB10 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{T6O2lEPTB;NUm5MlE5KG6P MmPrV2FPT0WU
HH NHHjZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF34T5lKSzVyPUW5PU41OyCwTR?= M1fhV3NCVkeHUh?=
EW-16 M4nrTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnfHTWM2OD14MEOuOVIhdk1? MYTTRW5ITVJ?
ES8 NIDKWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTZyNT6yNUBvVQ>? MnXZV2FPT0WU
HAL-01 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDadGVQUUN3ME22NFUvPjdibl2= NUPsTWxyW0GQR1XS
A204 NVTrc5d1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\ZPGlEPTB;NkOzMlkyKG6P M4HmNHNCVkeHUh?=
MHH-PREB-1 Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTkdpdZUUN3ME22N|YvQTlibl2= NEm0NlFUSU6JRWK=
EM-2 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTZ3MD62OEBvVQ>? NELjdpFUSU6JRWK=
BV-173 NWHoSYVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLYS29KSzVyPU[1Nk41QCCwTR?= NFPJPIVUSU6JRWK=
ONS-76 M4Xv[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTZ5Nz64NkBvVQ>? M3WydXNCVkeHUh?=
KM-H2 NYDqR24yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILNOIJKSzVyPU[5OU42PCCwTR?= NET3epRUSU6JRWK=
D-263MG NXHjT5FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTdzNz6xNkBvVQ>? NYLPTpBIW0GQR1XS
ES3 NIn0NJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTd{OD65N{BvVQ>? MVjTRW5ITVJ?
VA-ES-BJ NFLQ[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXqzU4ZXUUN3ME23N|IvOjdibl2= NVPVOJpVW0GQR1XS
NBsusSR NYDpR5U6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTMTWM2OD15NEKuPVkhdk1? MYTTRW5ITVJ?
NCI-H520 NXjmc4l3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvUU4JKSzVyPUe0Ok42OiCwTR?= MVzTRW5ITVJ?
ES5 NEnBSGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\uN4tKSzVyPUe1Nk45KG6P NXnvT3c2W0GQR1XS
T-24 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXzw[4ExUUN3ME23O|gvPzFibl2= NHXpeJVUSU6JRWK=
SW962 NU\XUos6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPxfGNEUUN3ME24NFgvPjNibl2= M{LrVHNCVkeHUh?=
EW-3 NULNRnVUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXRUHdvUUN3ME24NFgvPzZibl2= NVrsc3NyW0GQR1XS
RXF393 NILpfGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ruN2lEPTB;OEGyMlc6KG6P M3vkNHNCVkeHUh?=
U251 NUHzO3dqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLKRoZKUUN3ME24NVMvQDhibl2= M4\Sd3NCVkeHUh?=
CAMA-1 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2HWNGlEPTB;OEOzMlk1KG6P MleyV2FPT0WU
JVM-3 NFHMO|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTh3MT63PEBvVQ>? M4[5VXNCVkeHUh?=
COLO-800 NGS3dmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYjJR|UxRTh7Nz63PEBvVQ>? NEO5ZXVUSU6JRWK=
OVCAR-5 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rY[GlEPTB;OUCwMlEhdk1? M4HVNHNCVkeHUh?=
LB1047-RCC NEfz[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7pNFRvUUN3ME25NlcvPTZibl2= NWnBO3JFW0GQR1XS
SW954 NWnrTmNUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mlu5TWM2OD17MkmuOFEhdk1? M3ruOXNCVkeHUh?=
J-RT3-T3-5 NVTzb5hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13qRWlEPTB;OUO2MlA3KG6P MmfkV2FPT0WU
Mewo NXTGd2xrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr4VHZqUUN3ME25N|YvPiCwTR?= NVzLbHJSW0GQR1XS
NCI-H1770 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlW5TWM2OD17NECuOVUhdk1? M1TNWnNCVkeHUh?=
HO-1-N-1 NHK5dpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fyTmlEPTB;OU[yMlgyKG6P M2T1dHNCVkeHUh?=
HSC-3 NXXtPXVFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\B[mlEPTB;OU[2MlQ5KG6P MYnTRW5ITVJ?
TYK-nu MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTl7OD6yOUBvVQ>? NHzQWXRUSU6JRWK=
KYSE-150 M4DrVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LRW2lEPTB;MT6wNFA4PiEQvF2= NXvVUlZUW0GQR1XS
SN12C NInaXJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\jTWM2OD1zLkCwPFc2KM7:TR?= NUG4OVBFW0GQR1XS
MOLT-13 NEjwUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PWT2lEPTB;MT6wNVQzOSEQvF2= MUHTRW5ITVJ?
TE-11 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmjCTWM2OD1zLkC0PFEzKM7:TR?= MVfTRW5ITVJ?
DB NYmzcoQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzBTWM2OD1zLkC3Nlc{KM7:TR?= NHvDTnBUSU6JRWK=
CAL-39 MmjvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXlZ21lUUN3ME2xMlA4PTJ{IN88US=> MU\TRW5ITVJ?
A3-KAW M2r1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPjTWM2OD1zLkC4OFA5KM7:TR?= MYPTRW5ITVJ?
CHP-134 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTRTWM2OD1zLkGxPFA4KM7:TR?= NX7ESG94W0GQR1XS
TGW MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwMUKzPVUh|ryP NInJT3ZUSU6JRWK=
QIMR-WIL MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluwTWM2OD1zLkGzNVM1KM7:TR?= NXTCWoNJW0GQR1XS
NCI-SNU-1 NETzWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjTVo5OUUN3ME2xMlE3OzV2IN88US=> NH\BTZJUSU6JRWK=
CGTH-W-1 NYPEb3dnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfhWpFkUUN3ME2xMlE4OTh4IN88US=> NFf2VmRUSU6JRWK=
MHH-ES-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwMUe5PFYh|ryP MX7TRW5ITVJ?
LB2241-RCC M2Ps[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILwWHNKSzVyPUGuNVg3OiEQvF2= MXHTRW5ITVJ?
ML-2 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;G[GlEPTB;MT6yNFc{PCEQvF2= NITMe4FUSU6JRWK=
COR-L23 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3juOmlEPTB;MT6yNlk{OyEQvF2= M1rSOnNCVkeHUh?=
BFTC-905 NYrOT5o2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFSySpZKSzVyPUGuNlQzPjdizszN NWDveIY1W0GQR1XS
Hs-578-T Mn7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO4TWM2OD1zLkK1PFE4KM7:TR?= MX3TRW5ITVJ?
KG-1 MkTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rGSWlEPTB;MT6yOlY5PiEQvF2= Mnj2V2FPT0WU
HEL MkKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlT4TWM2OD1zLkK5N|M5KM7:TR?= MmLsV2FPT0WU
A549 MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXTTWM2OD1zLkK5N|k6KM7:TR?= NEO3SIdUSU6JRWK=
COLO-741 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTFwM{KwPFkh|ryP MojtV2FPT0WU
PC-3 M4\JbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HrbWlEPTB;MT6zOVIzOSEQvF2= MnvTV2FPT0WU
HOS M4PYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDLVHdKSzVyPUGuN|UzQTZizszN NV7reYt1W0GQR1XS
HT-1080 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkGxTWM2OD1zLkO3OVE6KM7:TR?= M3;0UHNCVkeHUh?=
TE-8 NUXBZ5VOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX74bG9oUUN3ME2xMlQyPzd2IN88US=> MUnTRW5ITVJ?
BHY NES1fJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIK4epJKSzVyPUGuOFY6OjNizszN MnLvV2FPT0WU
BB65-RCC MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e1XGlEPTB;MT61NFUzQCEQvF2= NITMU|hUSU6JRWK=
HN MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTFwNUSwO|Eh|ryP MWfTRW5ITVJ?
NCI-H441 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwNUS5NFch|ryP NFnYW|VUSU6JRWK=
RPMI-8866 NIjIUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;LTWM2OD1zLkW4OVA4KM7:TR?= MU\TRW5ITVJ?
CAL-62 NYDMeGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXOzVWQ3UUN3ME2xMlYxQDZ{IN88US=> MkLjV2FPT0WU
MG-63 NWrROo96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwNkG4NVMh|ryP NEC2OGRUSU6JRWK=
SK-LU-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j1R2lEPTB;MT62NlE2OiEQvF2= M{HocnNCVkeHUh?=
BCPAP NIDCZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfyTlQzUUN3ME2xMlY3PDV5IN88US=> MlHXV2FPT0WU
22RV1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXhUmVpUUN3ME2xMlY4QDR|IN88US=> NYDCTWQ5W0GQR1XS
T47D MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3JTWM2OD1zLk[4NFYyKM7:TR?= M2XmW3NCVkeHUh?=
MSTO-211H MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjzVVlKSzVyPUGuOlk3ODNizszN M4r4ZXNCVkeHUh?=
DEL NFHnXFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTFwN{CyO|Mh|ryP MX;TRW5ITVJ?
H4 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fPWWlEPTB;MT63N|IyOiEQvF2= MkS5V2FPT0WU
CAL-51 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4D2cWlEPTB;MT63OFg2PSEQvF2= MUTTRW5ITVJ?
ABC-1 NFvvSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHpXmxmUUN3ME2xMlc5PTh{IN88US=> M{\LbHNCVkeHUh?=
MZ2-MEL NHrBOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1viVmlEPTB;MT63PVU1OiEQvF2= MYPTRW5ITVJ?
YKG-1 Mn7ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLFTWM2OD1zLkixNFYyKM7:TR?= NE\RN4JUSU6JRWK=
KM12 NFT5PVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWT1PINRUUN3ME2xMlgyPjB{IN88US=> MV7TRW5ITVJ?
L-363 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXQfVlKSzVyPUGuPFc1OTJizszN NHy1RoFUSU6JRWK=
KU812 M2DOR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTFwOEmyPFIh|ryP Ml\pV2FPT0WU
LOXIMVI M3O2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlK5TWM2OD1zLkmxNlI5KM7:TR?= M1njdHNCVkeHUh?=
G-401 Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLmW2FNUUN3ME2xMlkzPDJ6IN88US=> MW\TRW5ITVJ?
SW780 MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlftTWM2OD1zLkm2NlQ3KM7:TR?= MonOV2FPT0WU
SW872 MoXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[2fVNKSzVyPUGuPVg{OyEQvF2= NEjQSGRUSU6JRWK=
NB7 NF[3R3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjLTWM2OD1zLkm5N|I{KM7:TR?= MoHSV2FPT0WU
T98G NIP4bI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX2foNKSzVyPUKuNFA3PjZizszN MW\TRW5ITVJ?
SW1710 NEPvWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo[4TWM2OD1{LkC2PVQ2KM7:TR?= NF;tboVUSU6JRWK=
NCI-H1573 NXXtclZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrrTWM2OD1{LkC3Nlk5KM7:TR?= MlvuV2FPT0WU
KE-37 NHjLcoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlroTWM2OD1{LkC4PVUyKM7:TR?= NWK5OnpjW0GQR1XS
786-0 MlX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXidVFvUUN3ME2yMlE2PDN7IN88US=> NHfiRWVUSU6JRWK=
SAS MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLOTWM2OD1{LkKwN|c1KM7:TR?= Mny0V2FPT0WU
CAL-54 NEXMXVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJwMkC0NVMh|ryP NFG3fXBUSU6JRWK=
SF268 M4jhPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTFTWM2OD1{LkKzNVIzKM7:TR?= NXvhXo0yW0GQR1XS
SW620 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M160Z2lEPTB;Mj6yOlE3QSEQvF2= M2rPWXNCVkeHUh?=
MN-60 NHTsdFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW5TWM2OD1{LkOxNFYh|ryP NGnRVoRUSU6JRWK=
EFO-27 M3XId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwM{KwOVgh|ryP Ml3mV2FPT0WU
NCI-H747 MnLWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK4PZFKSzVyPUKuN|IyQTlizszN NUm0O|BHW0GQR1XS
HCC2218 NVHteol1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTJwM{WzO|Qh|ryP NV7NSWxnW0GQR1XS
MIA-PaCa-2 NX;C[llST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPvO2loUUN3ME2yMlM3PDN5IN88US=> NVrnOG5WW0GQR1XS
SJSA-1 M2HxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP0W2Z{UUN3ME2yMlM4Pzl4IN88US=> Mmf0V2FPT0WU
RKO MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDDO|BDUUN3ME2yMlM5PDl4IN88US=> M4HM[XNCVkeHUh?=
NB6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTJwNECzO|Qh|ryP MV3TRW5ITVJ?
ES4 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7ufFZKSzVyPUKuOFU1OjJizszN MoTyV2FPT0WU
EGI-1 NXKwe5lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTJwNE[4PFMh|ryP NGXscVJUSU6JRWK=
CTV-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmO1TWM2OD1{LkWyO|c{KM7:TR?= MnfHV2FPT0WU
NCI-H1355 M3PP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzwTWM2OD1{LkW1PVUyKM7:TR?= NH7Xc2ZUSU6JRWK=
GT3TKB MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHp[VhKSzVyPUKuOVkyQTlizszN NWO2SlFvW0GQR1XS
SK-HEP-1 M3LZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF30OW1KSzVyPUKuOVkzPjZizszN M4TI[3NCVkeHUh?=
GAMG M3fYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrmO2FwUUN3ME2yMlU6Ozl2IN88US=> NUDVXZNiW0GQR1XS
SK-MES-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HFWmlEPTB;Mj62NVgxOyEQvF2= NH\qW2hUSU6JRWK=
RO82-W-1 NGG2UZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTJwNkKwOVch|ryP NFTWZ5NUSU6JRWK=
ECC10 NV;mXFVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TkeWlEPTB;Mj63NFIxPiEQvF2= M{HZOXNCVkeHUh?=
MCF7 Mo\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjH[XZKSzVyPUKuO|E1PjRizszN NYG2dG92W0GQR1XS
D-283MED NXq4ZoE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXKZYRKSzVyPUKuO|I1OyEQvF2= MkXLV2FPT0WU
RPMI-7951 NHO3fGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH2bWtKSzVyPUKuO|U3QTRizszN MlnyV2FPT0WU
Ramos-2G6-4C10 M{jH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnixTWM2OD1{Lke3NFk6KM7:TR?= M1XBfnNCVkeHUh?=
KGN Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\EbGlEPTB;Mj64NVg5PCEQvF2= NGDYVGlUSU6JRWK=
NUGC-3 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXqzSIN4UUN3ME2yMlgzPTB3IN88US=> MkLRV2FPT0WU
NCI-H292 MojTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny3TWM2OD1{Lki1NFU{KM7:TR?= Ml;LV2FPT0WU
Becker NFjaUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJwOUW4N|Ih|ryP M4nMfnNCVkeHUh?=
NCI-H1299 M{XBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[wfpNWUUN3ME2zMlA2OjZ|IN88US=> M4joSHNCVkeHUh?=
ETK-1 NIXLXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlj5TWM2OD1|LkC1OFMh|ryP NYXBZ|M1W0GQR1XS
TK10 NWPnWZQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTNwMkCxOlUh|ryP MV;TRW5ITVJ?
VMRC-RCZ MmDJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DOR2lEPTB;Mz6zOlQ5QCEQvF2= Mn\qV2FPT0WU
YH-13 NWD4OFlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTNwNESwO|kh|ryP NIrwd4pUSU6JRWK=
DU-145 MknWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\WVJhFUUN3ME2zMlQ3OjZ7IN88US=> MmX4V2FPT0WU
SW1088 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjYNlRKSzVyPUOuOFc1PyEQvF2= Ml;kV2FPT0WU
HOP-92 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWK4fm5RUUN3ME2zMlUxOzR{IN88US=> NIT4TFhUSU6JRWK=
KP-N-YS M2\5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjaOoVXUUN3ME2zMlYzOTN7IN88US=> NFzxW5RUSU6JRWK=
NCI-H460 NGfoVIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTNwNk[3N{DPxE1? NHLINnlUSU6JRWK=
U-2-OS NHWzSGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHZRWxKSzVyPUOuO|I2OzVizszN M4PmfnNCVkeHUh?=
A101D NHq4SpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU[xVnNtUUN3ME2zMlc3QTN4IN88US=> Mm\yV2FPT0WU
MDA-MB-231 M1\PbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LmVWlEPTB;Mz64NVk2OSEQvF2= MVTTRW5ITVJ?
IST-MES1 NIH1em1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTweVNKSzVyPUOuPFMzKM7:TR?= NYLP[WU5W0GQR1XS
COR-L105 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jBSGlEPTB;ND6wNVgh|ryP NHfJU4pUSU6JRWK=
NCI-H1437 MmDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjFPWNKSzVyPUSuNFI{ODJizszN NH\SUYdUSU6JRWK=
CAL-85-1 NGOyZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknsTWM2OD12LkCyOFYyKM7:TR?= MUnTRW5ITVJ?
MZ1-PC M{PEbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzWTWM2OD12LkG4OVU3KM7:TR?= MoTzV2FPT0WU
VM-CUB-1 NGjJb2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3HTWM2OD12LkOxNlg1KM7:TR?= MlT4V2FPT0WU
CHL-1 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLGTWM2OD12LkOyNVY6KM7:TR?= NYjpc4VkW0GQR1XS
MDA-MB-361 NGnmR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTRwM{OxOVMh|ryP MXHTRW5ITVJ?
NCI-H661 NEXrdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnNVpBrUUN3ME20MlUxODl{IN88US=> NFi3eVRUSU6JRWK=
EW-11 NWnlT3JNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2f6R2lEPTB;ND61NlI{OSEQvF2= NVGyRZM2W0GQR1XS
BEN NFPjeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrFTWM2OD12LkWyPFE2KM7:TR?= MlrVV2FPT0WU
BFTC-909 M3;oeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojTTWM2OD12LkW2Nlc2KM7:TR?= M{L0OHNCVkeHUh?=
NCI-H2087 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\lTWM2OD12LkW4NVY1KM7:TR?= NHTkZVlUSU6JRWK=
RVH-421 NW\FWJZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTRwNk[2PUDPxE1? NGTKe5RUSU6JRWK=
P30-OHK M4\2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUDJR|UxRTRwNkiwNFgh|ryP MorRV2FPT0WU
NCI-H28 NYT0W2hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVTxOnZHUUN3ME20MlgyPjZzIN88US=> MYrTRW5ITVJ?
ES6 NETLU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojrTWM2OD12LkizNFE3KM7:TR?= NWXQNmg5W0GQR1XS
769-P NED2c4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fqN2lEPTB;ND64OVkzPiEQvF2= MULTRW5ITVJ?
OE33 M2HSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3xZZF2UUN3ME20Mlg5OTZzIN88US=> NYTsWnA1W0GQR1XS
SW982 M4HIVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTRwOUWwOlEh|ryP NFXwZ3pUSU6JRWK=
A388 M3rzOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HMcWlEPTB;NT6wNlk5OyEQvF2= NFXFWIdUSU6JRWK=
TI-73 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TKe2lEPTB;NT6wOlE6PCEQvF2= MW\TRW5ITVJ?
HCT-116 MlHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLUU3BKSzVyPUWuNFk5QDlizszN MYDTRW5ITVJ?
HuP-T3 Mo\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTVwMUi3NFkh|ryP NWPl[Hk1W0GQR1XS
G-402 NHLrcmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPI[W5wUUN3ME21MlE6PDF4IN88US=> MYHTRW5ITVJ?
NCI-H1792 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\Ye2lEPTB;NT6yOFYzOiEQvF2= NFrFO5RUSU6JRWK=
NCI-H209 NGXZd29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XDSmlEPTB;NT6yOVk1OiEQvF2= MkfqV2FPT0WU
NCI-H1650 MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTSTWM2OD13LkOwOlM1KM7:TR?= NEC0bmJUSU6JRWK=
LCLC-97TM1 Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTzepVKSzVyPUWuN|E5ODhizszN MoXWV2FPT0WU
S-117 Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTVwM{[5O|Yh|ryP MkTJV2FPT0WU
GI-ME-N MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrabnBKSzVyPUWuN|k3QDFizszN MoHGV2FPT0WU
NCI-H2122 MoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTVwNEmzPVch|ryP MnvlV2FPT0WU
NCI-H1793 NU\lOWp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rCNGlEPTB;NT62O|U6OyEQvF2= NIXaR2pUSU6JRWK=
C2BBe1 NVjoPHdrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojETWM2OD13LkewNFg5KM7:TR?= NXn0bpI1W0GQR1XS
TE-12 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jYUmlEPTB;NT64NFU2PiEQvF2= MnTlV2FPT0WU
LCLC-103H NHnMRY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPnV|IxUUN3ME21MlkyPyEQvF2= M4fx[3NCVkeHUh?=
A673 M3S2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\uTWM2OD13LkmxPVMzKM7:TR?= M3fzUnNCVkeHUh?=
BB30-HNC NWTIO4FpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTVwOUizOkDPxE1? NEP2cZBUSU6JRWK=
SF295 NIW0R3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlK1TWM2OD14LkCwOFIzKM7:TR?= MX;TRW5ITVJ?
KU-19-19 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGTlNoJKSzVyPU[uNFE4OzFizszN MXLTRW5ITVJ?
CFPAC-1 NUXaNJU{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTyTWM2OD14LkC0OFQ{KM7:TR?= M3rnN3NCVkeHUh?=
LoVo MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjGdY1KSzVyPU[uNFUxPjNizszN MkXoV2FPT0WU
8505C MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfNepBKSzVyPU[uNFc2PzNizszN NX\WZ3NTW0GQR1XS
GMS-10 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHqfpE6UUN3ME22MlE2ODB{IN88US=> MlrVV2FPT0WU
Ca9-22 MmrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvFZYZKSzVyPU[uNVY4OSEQvF2= M{jZRXNCVkeHUh?=
DOK MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTZwMkKwO|Ih|ryP NYDjVI1PW0GQR1XS
FADU MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvCRoN4UUN3ME22MlI3ODN7IN88US=> NHHJO2FUSU6JRWK=
BxPC-3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\NOWlEPTB;Nj6yO|MzKM7:TR?= MlO1V2FPT0WU
CAL-33 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH0TWM2OD14LkK5NlAyKM7:TR?= MWrTRW5ITVJ?
SHP-77 MoHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorDTWM2OD14LkOxOVEzKM7:TR?= Ml72V2FPT0WU
LXF-289 NVeyd3FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXw[213UUN3ME22MlM{PDV3IN88US=> NVL3eolIW0GQR1XS
GB-1 M{DENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTZwM{iyJO69VQ>? NV3rTW1HW0GQR1XS
KS-1 NUXQeWZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHTTWM2OD14LkO4OFQ4KM7:TR?= M1OydnNCVkeHUh?=
D-502MG MmHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlHYTWM2OD14LkSyN|c3KM7:TR?= Mlm0V2FPT0WU
LAN-6 NFLDS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS4OGxKSzVyPU[uOVExOjNizszN Mn\sV2FPT0WU
H-EMC-SS NID2OmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrZ[JFKSzVyPU[uOVYyPDdizszN Mn[4V2FPT0WU
LC-2-ad M1Xm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTZwNkCwO|Yh|ryP MXnTRW5ITVJ?
NCI-H1693 NX7zXVN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S1dmlEPTB;Nj62NlIyPSEQvF2= M{\YOXNCVkeHUh?=
SK-N-FI MmjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLKdIFKSzVyPU[uO|UxPDRizszN M1jY[XNCVkeHUh?=
D-423MG NXflWZRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1W4VGlEPTB;Nj63OlEyPyEQvF2= MXjTRW5ITVJ?
KNS-42 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVO3eWZ[UUN3ME22Mlc5OTl5IN88US=> MoPWV2FPT0WU
GCT MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnH0TWM2OD14LkmzPEDPxE1? M1TCWHNCVkeHUh?=
DSH1 M4\EbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTTTWM2OD15LkC2N|Mh|ryP M2HQRnNCVkeHUh?=
D-247MG M4ixWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHzOGF3UUN3ME23MlA4QDhzIN88US=> MY\TRW5ITVJ?
NCI-SNU-5 NWXFc4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLsfIZKSzVyPUeuNVg{PzFizszN NFnhTWxUSU6JRWK=
TE-6 NELzUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXZUIY6UUN3ME23MlIxPjBzIN88US=> MU\TRW5ITVJ?
NOMO-1 NGnicI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1e4RmlEPTB;Nz6yNlEzPyEQvF2= NFfQfnJUSU6JRWK=
NB17 NV;MRoV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTdwM{CzNFkh|ryP MnHpV2FPT0WU
EW-22 NXviSJF3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D2OWlEPTB;Nz6zOFM1QCEQvF2= M4TvVnNCVkeHUh?=
EW-13 M{nIb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HOdGlEPTB;Nz6zOVE3OiEQvF2= M1q1bHNCVkeHUh?=
DOHH-2 NGXHW2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTdwNESwNkDPxE1? NX3tVHI6W0GQR1XS
TGBC1TKB MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTdwNEm4PVkh|ryP M{DnVnNCVkeHUh?=
GR-ST NUjiemxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIT0UpJKSzVyPUeuOVI2QTRizszN NFzueXVUSU6JRWK=
KYSE-520 NYDUWnplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTae|hKUUN3ME23MlU2PTF3IN88US=> NFrZU|hUSU6JRWK=
CAPAN-1 M3;BOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUmxW4NWUUN3ME23MlU6PTFizszN Mn;nV2FPT0WU
HCE-4 NI\ueZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjNfoVKSzVyPUeuOlIzPzlizszN NYT6fZREW0GQR1XS
MLMA M1nz[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVroSXg2UUN3ME23MlYzQTV5IN88US=> M{fF[nNCVkeHUh?=
HT-144 NIHWTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vYXmlEPTB;Nz62OVM3QCEQvF2= MY\TRW5ITVJ?
KYSE-180 NX7Bd3BlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrwTWM2OD15LkexNVY6KM7:TR?= M2[3UXNCVkeHUh?=
TE-5 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HIeWlEPTB;Nz65OVk4OSEQvF2= M{fLOnNCVkeHUh?=
IGROV-1 Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTdwOUi1OVEh|ryP MX;TRW5ITVJ?
NCI-H1581 NI\uO|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRThwMEGyJO69VQ>? NWTTellIW0GQR1XS
SW1990 M4PQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFW0ZmdKSzVyPUiuNFQ3PTlizszN Mnv1V2FPT0WU
EFM-19 M1Tjdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHHRXBsUUN3ME24MlA5PTR3IN88US=> NVPKXHVQW0GQR1XS
OGR-1 NVqzOGcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HhWWlEPTB;OD60N|AzOyEQvF2= NG\peINUSU6JRWK=
U-118-MG NVXuUGZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDabndKSzVyPUiuOFM1PjNizszN M1nFfnNCVkeHUh?=
SK-OV-3 M4rV[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHwOJhKSzVyPUiuOFY4PjVizszN MoO2V2FPT0WU
KNS-62 NGe1N4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvrWlNKSzVyPUiuOVE4PjFizszN M3zNTHNCVkeHUh?=
GOTO NVnOVVV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M16zRWlEPTB;OD61O|Y{PSEQvF2= NEPtd|ZUSU6JRWK=
8305C M370XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH[yTIhKSzVyPUiuO|A1QDRizszN MYXTRW5ITVJ?
RPMI-2650 NHLlcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRThwN{G5OVUh|ryP NXHiOIdHW0GQR1XS
NEC8 M{fNR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRThwN{SzNFch|ryP NG\yZ5FUSU6JRWK=
KYSE-450 NYm5UlB1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRThwOE[1OFgh|ryP MknLV2FPT0WU
RMG-I MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2r4TmlEPTB;OT6xOFA2QCEQvF2= MofHV2FPT0WU
CAKI-1 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\SOWlEPTB;OT6zNVk4QSEQvF2= NEL3cnFUSU6JRWK=
KYSE-510 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnDWVNKSzVyPUmuN|U4PzhizszN MkTVV2FPT0WU
A4-Fuk NYLjTZBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Li[mlEPTB;OT6zOlcxOSEQvF2= NIPzWmJUSU6JRWK=
AN3-CA NWXW[mo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFz1U25KSzVyPUmuOFU1PDRizszN MVHTRW5ITVJ?
SK-N-DZ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVXJR|UxRTlwN{K4OFkh|ryP MYXTRW5ITVJ?
HSC-2 NFiyUVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTlwN{[2Nlkh|ryP Ml32V2FPT0WU
EW-1 MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MonGTWM2OD17Lke5N|Y6KM7:TR?= M4PCc3NCVkeHUh?=
D-566MG M4r4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjJUopKSzVyPUmuPFM3PjRizszN M1:yTnNCVkeHUh?=
COLO-792 M{HveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHVVGhLUUN3ME25Mlk5PzR4IN88US=> M2fpWHNCVkeHUh?=
TE-10 NV3he3BET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULnOZVrUUN3ME2xNE4xOzl4IN88US=> MWfTRW5ITVJ?
NCI-H650 M{\ZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTFyLkSyPFYh|ryP MVzTRW5ITVJ?
U-266 MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPK[JUxUUN3ME2xNE41PTVizszN MkWyV2FPT0WU
Detroit562 M4rNfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXRNmJWUUN3ME2xNU4xPTF3IN88US=> M1[3OnNCVkeHUh?=
NH-12 NXS0OJh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTFzLkG0OFYh|ryP NUPXenhPW0GQR1XS
CO-314 NWPSOnJiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmmzTWM2OD1zMT6yPFQzKM7:TR?= MkTtV2FPT0WU
IST-MEL1 NYnyO5hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTFzLkWzNlMh|ryP M2HtTXNCVkeHUh?=
KNS-81-FD MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWKwc2dRUUN3ME2xNU42PTJ5IN88US=> NYHUSpgzW0GQR1XS
SW1463 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfVOFBKSzVyPUGxMlU6QDlizszN MWrTRW5ITVJ?
NCI-H23 MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmn1TWM2OD1zMT62OVUzKM7:TR?= NV3nUHk1W0GQR1XS
SK-MEL-2 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPDUGhHUUN3ME2xNU44OTl5IN88US=> NXTkeod4W0GQR1XS
NB13 Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnNTWM2OD1zMj6xOFk2KM7:TR?= NEC0T5pUSU6JRWK=
Daoy NHvqToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33HRmlEPTB;MUKuNlg2PiEQvF2= MWPTRW5ITVJ?
NCI-H1623 M3zYT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqzTWM2OD1zMj6zPFAyKM7:TR?= M{HGUHNCVkeHUh?=
NMC-G1 MnLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljXTWM2OD1zMj63NVch|ryP NYjkSpZGW0GQR1XS
DK-MG MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGXtVXhKSzVyPUGyMlk1QDJizszN NXm0NmZTW0GQR1XS
TCCSUP MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEX2PFZKSzVyPUGzMlEzQDRizszN NF:xfodUSU6JRWK=
SCC-15 M33JTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrBcXFKSzVyPUGzMlI3PTFizszN MorGV2FPT0WU
NOS-1 Mny5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDQTWM2OD1zMz6yPFk{KM7:TR?= MXXTRW5ITVJ?
RH-1 NFn2b5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XQeGlEPTB;MUOuN|A{PyEQvF2= NFnSWJdUSU6JRWK=
SK-MEL-3 NVzBdnNLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTF|LkO3Nlgh|ryP NGDXbZdUSU6JRWK=
NB5 Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF|LkSwOlch|ryP M3POTXNCVkeHUh?=
SNU-387 MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVmzXml3UUN3ME2xN{42ODd{IN88US=> MVrTRW5ITVJ?
CAL-120 NUSwSWNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e5d2lEPTB;MUOuOlcyQCEQvF2= MWfTRW5ITVJ?
Mo-T MmPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTF|LkewO{DPxE1? Mk\aV2FPT0WU
LNCaP-Clone-FGC M3PUNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlW1TWM2OD1zMz63PVkzKM7:TR?= MYnTRW5ITVJ?
CAN MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2SyR2lEPTB;MUSuNFI5QCEQvF2= NInSZnBUSU6JRWK=
SK-MEL-30 M4XFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4ewN2lEPTB;MUSuNFY{KM7:TR?= M3X5SnNCVkeHUh?=
COLO-678 NHPjTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUDRcmZnUUN3ME2xOE4xQDJ{IN88US=> MoLiV2FPT0WU
SCC-9 NYfKd4pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3MU2ZtUUN3ME2xOE4yODJzIN88US=> NHzFS2hUSU6JRWK=
KINGS-1 NWHYdGdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\zTWM2OD1zND6xOFAzKM7:TR?= MofzV2FPT0WU
SL-513 NIHVe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnQcZpKSzVyPUG0MlE5PyEQvF2= NIW4bppUSU6JRWK=
HLE MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HmW2lEPTB;MUSuN|g2OiEQvF2= MUXTRW5ITVJ?
SW1573 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\xPZZKSzVyPUG0MlQ1OzVizszN NXzMTGtqW0GQR1XS
KYSE-140 NGHHbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrWTWM2OD1zND62N|I4KM7:TR?= M3rzb3NCVkeHUh?=
SK-PN-DW M3K2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3P4[WlEPTB;MUSuPFAxOSEQvF2= Mo\NV2FPT0WU
A253 NELSU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PzdWlEPTB;MUWuNFYzPSEQvF2= M2DBUXNCVkeHUh?=
CAL-12T MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTF3LkS2OlIh|ryP NHLmfmlUSU6JRWK=
COLO-679 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{TucWlEPTB;MUWuO|Y5OyEQvF2= NF6y[FZUSU6JRWK=
UACC-257 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfDVXdKSzVyPUG2MlEzODFizszN NWHhXo1xW0GQR1XS
U-87-MG NYHvT|lnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDxUHUzUUN3ME2xOk4{PTJ|IN88US=> MX;TRW5ITVJ?
HCC1806 NGnPbFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XXTWlEPTB;MU[uO|A4OSEQvF2= NEH4PHVUSU6JRWK=
NCI-H2170 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jZeWlEPTB;MUeuNlQ1QCEQvF2= MX7TRW5ITVJ?
AGS MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLaNHlKSzVyPUG3MlM5ODhizszN M2HrdHNCVkeHUh?=
MEL-HO Mn25S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTtTWM2OD1zNz63OVA{KM7:TR?= MmTaV2FPT0WU
SW48 NYDKVnd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2r0SGlEPTB;MUeuO|cyPiEQvF2= NEnQ[nlUSU6JRWK=
HuP-T4 NVz2fWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojsTWM2OD1zOD6wNlA3KM7:TR?= M3HqU3NCVkeHUh?=
NCI-H720 Mn6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fhcmlEPTB;MUiuNVQxOiEQvF2= M3\senNCVkeHUh?=
RCC10RGB MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF6LkG2PVch|ryP M3rpSHNCVkeHUh?=
HD-MY-Z MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInmUoZKSzVyPUG4MlIzPTRizszN NIHFWmZUSU6JRWK=
A427 NUjVPZNZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTF6LkWwPVQh|ryP M3XNbHNCVkeHUh?=
HCC2998 NEOxUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfqTWM2OD1zOD62NFUyKM7:TR?= NWXTdGs1W0GQR1XS
EPLC-272H NEDEVFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTF7LkC0N|Qh|ryP M1yxR3NCVkeHUh?=
C32 M3HNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\XN2lEPTB;MUmuNFQ2KM7:TR?= NHLKNY1USU6JRWK=
UMC-11 M2DMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Yd4hKSzVyPUG5MlIyOjNizszN M1rpVnNCVkeHUh?=
CaR-1 NUT5fnpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:4OmlEPTB;MUmuOlgxPCEQvF2= NUfLc3FpW0GQR1XS
KYSE-410 Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPh[YppUUN3ME2xPU46OTN7IN88US=> NWXUe5p6W0GQR1XS
HuCCT1 M1e0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7YUJNKSzVyPUKwMlYzQTRizszN M2LKcnNCVkeHUh?=
LB996-RCC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjSTWM2OD1{MD63NVY5KM7:TR?= MnLWV2FPT0WU
KYSE-70 M2C4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfISXVjUUN3ME2yNE45ODV7IN88US=> MoTUV2FPT0WU
CAL-72 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTJyLkmxOUDPxE1? MoXQV2FPT0WU
Capan-2 M2rLV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3mO5RKSzVyPUKxMlA1OTNizszN MnnqV2FPT0WU
PANC-08-13 Ml3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXvU3AyUUN3ME2yNU4zPTF3IN88US=> NEDZeHhUSU6JRWK=
SBC-1 NYXFfoZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTJzLkOwPFEh|ryP MUTTRW5ITVJ?
MFM-223 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3WcYNKSzVyPUKxMlM{PDJizszN MnjkV2FPT0WU
BB49-HNC NVvzUFRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Ts[GlEPTB;MkGuOVcyPiEQvF2= NIS4e4VUSU6JRWK=
SH-4 M3HUV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPXTWM2OD1{MT62OlE5KM7:TR?= M4Ltc3NCVkeHUh?=
HuO9 NIPkdIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3my[WlEPTB;MkGuPVgzPSEQvF2= MmrWV2FPT0WU
AM-38 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTpTmVKSzVyPUKyMlA1QDVizszN NVrsNVBXW0GQR1XS
A431 NYm0eIRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG3TWM2OD1{Mz6yNVE6KM7:TR?= NEPsSnFUSU6JRWK=
YAPC M1XqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkf3TWM2OD1{Mz6yOlUyKM7:TR?= NGO3fY9USU6JRWK=
LU-139 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3YNXhlUUN3ME2yN{41QDB7IN88US=> M1v3TXNCVkeHUh?=
HEC-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXpXGhiUUN3ME2yN{41QTN5IN88US=> MYnTRW5ITVJ?
SCC-25 M1vxOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK2TJVKSzVyPUK0MlMxODZizszN MmLSV2FPT0WU
HT-29 MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTFcYdNUUN3ME2yOE4{QDJ|IN88US=> NGnubZlUSU6JRWK=
PC-14 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn2TWM2OD1{ND62OVcyKM7:TR?= MY\TRW5ITVJ?
Calu-6 M4fFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlfNTWM2OD1{NT61NFcyKM7:TR?= Mlr0V2FPT0WU
SJRH30 MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTJ3Lk[0PVYh|ryP Mkn4V2FPT0WU
ChaGo-K-1 NX3FVmxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnY[ZJKSzVyPUK2MlE3OjlizszN Mn3yV2FPT0WU
IA-LM MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTCW3JKSzVyPUK2MlM3PDVizszN MXzTRW5ITVJ?
GP5d MmLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml[1TWM2OD1{Nj60OFkyKM7:TR?= M1vXXnNCVkeHUh?=
NCI-H2291 MkG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLTdXZKSzVyPUK2MlY2PDFizszN NVPK[5hVW0GQR1XS
BALL-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL1TWM2OD1{Nj65N|k4KM7:TR?= M4nQXXNCVkeHUh?=
HCC1954 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXOTWM2OD1{Nj65PFA5KM7:TR?= M{j4[nNCVkeHUh?=
NCI-H2452 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ5LkSxOlMh|ryP M2PMVHNCVkeHUh?=
LU-99A NFLCd4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zFcWlEPTB;MkeuOVU5OiEQvF2= NUHqNnFIW0GQR1XS
NTERA-S-cl-D1 Ml3SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXKeYtKSzVyPUK3MlczQTlizszN NYjVPZNXW0GQR1XS
PANC-10-05 NHPjRWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlO0TWM2OD1{Nz63O|c2KM7:TR?= MXTTRW5ITVJ?
NCI-H2405 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnhdXc4UUN3ME2yO{46Ozh5IN88US=> NGX2[oFUSU6JRWK=
MDA-MB-415 Mo\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJ6LkSxN|ch|ryP MUnTRW5ITVJ?
NCI-H2342 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTJ6LkWyPFEh|ryP M2nKU3NCVkeHUh?=
TGBC24TKB M1K5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DnU2lEPTB;MkiuO|EyPyEQvF2= NXnwRnY4W0GQR1XS
LU-134-A NXvhXll[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrYNJZKSzVyPUK4MlkzPjFizszN Ml7qV2FPT0WU
SCC-4 NGLJPXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILBVHRKSzVyPUOxMlA1QTRizszN NYHBd4I5W0GQR1XS
Saos-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTNzLkmzNFYh|ryP NYO4fmkyW0GQR1XS
RERF-LC-MS NXLXbnY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTN{LkiyN|Eh|ryP Mn72V2FPT0WU
M14 NVn0e2RxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnEUXZZUUN3ME2zNk46PzZ2IN88US=> MlrDV2FPT0WU
HPAF-II M13weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVm5fZJOUUN3ME2zN{42ODFzIN88US=> M1WxcXNCVkeHUh?=
NCI-H1755 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojITWM2OD1|ND6zN|A2KM7:TR?= MXHTRW5ITVJ?
D-392MG MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkixTWM2OD1|NT64Olc1KM7:TR?= NIfvSIJUSU6JRWK=
A704 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUj1[ppbUUN3ME2zOk4xPDJ5IN88US=> NGjqOGlUSU6JRWK=
CP50-MEL-B NUjIRpo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vBWmlEPTB;M{[uNVkyOSEQvF2= NGCyZmhUSU6JRWK=
EW-18 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LDR2lEPTB;M{[uOFUzKM7:TR?= Ml;XV2FPT0WU
WM-115 NFzld5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELHe4JKSzVyPUO2MlgxQTlizszN NHH0WJRUSU6JRWK=
LU-65 MlLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTN5LkG0NVch|ryP M2jqdXNCVkeHUh?=
NCI-H1563 NYHBelJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTN5LkK0PFQh|ryP M4nvW3NCVkeHUh?=
DBTRG-05MG NFe4e5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PhVWlEPTB;M{iuNFY6OSEQvF2= MWTTRW5ITVJ?
NCI-H630 NF7wXHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID3fHpKSzVyPUO4MlQ4OTRizszN NF\OOlNUSU6JRWK=
NCI-H1155 NX;zd3FJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTRTWM2OD1|OT6yOFIh|ryP M4XBV3NCVkeHUh?=
OVACR-3 MmfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXPWYh7UUN3ME2zPU46OTl3IN88US=> NFjtfGFUSU6JRWK=
OAW-42 M2\5fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzWdlJ1UUN3ME20NE41OjV6IN88US=> NVzpXm5OW0GQR1XS
JVM-2 MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2P3fGlEPTB;NEGuNlQyPSEQvF2= M3XHTHNCVkeHUh?=
C3A NH23e5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTRzLkO0OFch|ryP MV\TRW5ITVJ?
HT55 M3e2TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDvOIhKSzVyPUSyMlI5PDFizszN NX3wOplCW0GQR1XS
OVCAR-4 NYLYOJZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvD[HloUUN3ME20Nk4zQTd2IN88US=> NX;xW3Z6W0GQR1XS
MEG-01 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjoOIhKSzVyPUSyMlQ3OTZizszN NWDwfXJbW0GQR1XS
NCI-H82 NGfScJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW4V5FrUUN3ME20N{46QDl{IN88US=> NXPzbnBUW0GQR1XS
JEG-3 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWO1[GpjUUN3ME20OE46PDdizszN MkfjV2FPT0WU
BPH-1 MnnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLrPXJsUUN3ME20Ok4{QTl6IN88US=> NIO5OpFUSU6JRWK=
MPP-89 NYDqd3FOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWHJR|UxRTR5LkK4PVgh|ryP MVfTRW5ITVJ?
ALL-PO MkXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LUUGlEPTB;NEeuOFE5QCEQvF2= NELKWVFUSU6JRWK=
HT NYHMUGpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHtR|JtUUN3ME20O{41QTJizszN NIHBSIVUSU6JRWK=
NCI-H2347 NGXKNpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rKSmlEPTB;NEiuNFcyPSEQvF2= M2XVTHNCVkeHUh?=
A2780 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG1dYptUUN3ME20PU41OjJ6IN88US=> MULTRW5ITVJ?
KARPAS-299 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTR7LkWxNVkh|ryP MkfnV2FPT0WU
NCI-H1651 NH7wSpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPvTWM2OD12OT64PFIyKM7:TR?= M1zQdXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]

+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl

CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03870919 Not yet recruiting Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer May 15 2019 Not Applicable
NCT03870919 Not yet recruiting Breast Cancer Stage IV|Radiotherapy|Surgery UNICANCER|Pfizer May 15 2019 Not Applicable
NCT03820830 Not yet recruiting Breast Cancer Recurrent International Breast Cancer Study Group|Pfizer May 1 2019 Phase 3
NCT03820830 Not yet recruiting Breast Cancer Recurrent International Breast Cancer Study Group|Pfizer May 1 2019 Phase 3
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer May 7 2019 Phase 2
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer May 7 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

Related CDK Products3

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID